Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.68
<$0.01(0.15%)
At close: 4:00 PM EST
$1.68
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume1.63M
Average Volume (3M)12.67M
Market Cap
$923.79M
Enterprise Value$934.92
Total Cash (Recent Filing)$314.29M
Total Debt (Recent Filing)$251.84M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume8,894,956
30 Day Avg. Volume12,670,909
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside138.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$233.84M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue RampA multi-year inflection in revenue and a 31% YoY Q1 increase indicate durable commercial adoption of RYTELO. Persistent top-line growth buttresses scale economies, funds continued R&D and commercialization, and improves the firm's ability to invest toward sustainable margins over 2–6 months.
Commercial Traction & Account ExpansionQuarterly demand growth and increasing prescribing accounts reflect expanding physician acceptance and deeper market penetration. These structural commercial gains support repeatable revenue streams, better forecasting, and higher long‑term uptake potential across treatment lines.
Balance Sheet CushionA meaningful equity cushion and manageable leverage provide financing flexibility while the company scales. This capital structure reduces immediate refinancing risk, enables continued commercial and clinical investment, and supports execution through upcoming milestones over the medium term.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flows signal the company is still consumption‑driven rather than self‑funding. Sustained cash burn requires either strong sustained revenue growth, further cost cuts, or external financing, all of which materially affect strategic flexibility over the coming months.
Widening Gross‑to‑Net PressureA structurally higher gross‑to‑net reduces realized revenue per unit and compresses margins even as volumes grow. Persistent 20%+ adjustments from payer mix and contracting materially erode cash conversion and make it harder to translate sales growth into durable profitability.
Clinical Outcome UncertaintyKey trial readouts are pivotal for label expansion, guideline uptake, and long‑term commercial trajectory. A negative or neutral interim could slow adoption and reduce upside across indications, altering revenue durability and the company’s ability to justify continued commercial investment.
Geron News
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $923.79M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 13 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.01.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 641,521,000 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (138.10% Upside)
$4.00 (138.10% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 7.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Stock 12 Month Forecast
Average Price Target
$4.00
▲(138.10% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.33% Mutual Funds
0.28% Other Institutional Investors
72.45% Public Companies and
Individual Investors